Regulus, which is backed by multiple pharmaceutical groups, will have a market capitalisation of about $239m if it prices at the middle of its range.

Annovation won backing from healthcare company The Medicines Company and venture investors including Atlas Venture.

Biofirm Aerpio Therapeutics secures a $27m series A round, led by Novartis, an existing backer of parent company Akebia.

Intel-backed cardiovascular diagnostics firm CardioDx raises $58m in a venture round joined by Temasek and existing investors.

Sanofi Aventis-backed biopharma company Regulus Therapeutics preps for its anticipated IPO.

Consure was started last year after grants from Stanford University-India Biodesign, and medical device maker Johnson & Johnson.